Results for tag: "Briviact"

Briviact is a central nervous system (CNS) drug used to treat partial-onset seizures in adults and adolescents aged 16 years and older. It is a selective, high-affinity, competitive antagonist of the α2δ subunit of voltage-gated calcium channels. Briviact works by blocking the release of certain neurotransmitters in the brain, which helps to reduce the frequency of seizures. It is available in tablet form and is taken orally once a day. The Briviact market is a rapidly growing segment of the CNS drug market. It is driven by the increasing prevalence of epilepsy and other seizure disorders, as well as the need for more effective treatments. The market is expected to continue to grow in the coming years, as more patients seek out treatments for their conditions. Some of the major companies in the Briviact market include UCB, Inc., Eisai Co., Ltd., and Sunovion Pharmaceuticals, Inc. Show Less Read more